These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 30231226)

  • 1. Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia.
    DiNardo CD
    N Engl J Med; 2018 Sep; 379(12):1186. PubMed ID: 30231226
    [No Abstract]   [Full Text] [Related]  

  • 2. Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia.
    Yun S; Vincelette ND
    N Engl J Med; 2018 Sep; 379(12):1186. PubMed ID: 30260155
    [No Abstract]   [Full Text] [Related]  

  • 3. Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia.
    Sahin I
    N Engl J Med; 2018 Sep; 379(12):1186. PubMed ID: 30260154
    [No Abstract]   [Full Text] [Related]  

  • 4. Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation.
    Tabata MM; Chase M; Kwong BY; Novoa RA; Fernandez-Pol S
    J Cutan Pathol; 2020 Nov; 47(11):1042-1045. PubMed ID: 32588467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
    Norsworthy KJ; Luo L; Hsu V; Gudi R; Dorff SE; Przepiorka D; Deisseroth A; Shen YL; Sheth CM; Charlab R; Williams GM; Goldberg KB; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Jun; 25(11):3205-3209. PubMed ID: 30692099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia.
    Dunn-Valadez S; Bathini S; Elston C; Rangaraju S; Stasi AD; Worth S; Morlote D; Harada S; Vachhani P
    Cancer Treat Res Commun; 2022; 31():100560. PubMed ID: 35460975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Induction of Hypomethylation with Ivosidenib and 5-Azacitidine Curative Regimen against IDH1-Mutated Acute Myeloid Leukemia?
    Takahashi K
    Anticancer Agents Med Chem; 2023; 23(8):864-866. PubMed ID: 36503457
    [No Abstract]   [Full Text] [Related]  

  • 8. Ivosidenib Deemed Safe, Effective in AML.
    Cancer Discov; 2018 Aug; 8(8):OF1. PubMed ID: 29934313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ivosidenib and Azacitidine in IDH1-Mutated AML.
    Goodman AM; Mohyuddin GR; Prasad V
    N Engl J Med; 2022 Jun; 386(26):2536. PubMed ID: 35767449
    [No Abstract]   [Full Text] [Related]  

  • 10. Ivosidenib and Azacitidine in IDH1-Mutated AML.
    Gil-Sierra MD; Briceño-Casado MP; Sierra-Sanchez JF
    N Engl J Med; 2022 Jun; 386(26):2535-2536. PubMed ID: 35767448
    [No Abstract]   [Full Text] [Related]  

  • 11. Ivosidenib and Azacitidine in IDH1-Mutated AML. Reply.
    Montesinos P; de Botton S; Döhner H
    N Engl J Med; 2022 Jun; 386(26):2536-2537. PubMed ID: 35767450
    [No Abstract]   [Full Text] [Related]  

  • 12. [Ivosidenib in the treatment of patients with cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy].
    Rabehi T; Quesada S
    Bull Cancer; 2023 Dec; 110(12):1230-1231. PubMed ID: 37704495
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia.
    Yue Z; Pan C; Wang S; N Tse A; Sheng Y
    Eur J Clin Pharmacol; 2024 Jan; 80(1):105-113. PubMed ID: 37917187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection of the IDH1 gene mutation in acute myeloid leukemia by PCR-high resolution melting analysis].
    Lin J; Qian J; Yao DM
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):484-6. PubMed ID: 22213873
    [No Abstract]   [Full Text] [Related]  

  • 15. Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis.
    Lin J; Qian J; Yao DM; Li Y; Yang J; Chen Q; Chai HY; Xiao GF; Xu WR
    Clin Biochem; 2011 Jul; 44(10-11):779-83. PubMed ID: 21539821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH mutations in glioma and acute myeloid leukemia.
    Dang L; Jin S; Su SM
    Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.
    Balss J; Thiede C; Bochtler T; Okun JG; Saadati M; Benner A; Pusch S; Ehninger G; Schaich M; Ho AD; von Deimling A; Krämer A; Heilig CE
    Leukemia; 2016 Apr; 30(4):782-8. PubMed ID: 26582645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ivosidenib effective in IDH1-mutant AML.
    Sidaway P
    Nat Rev Clin Oncol; 2018 Aug; 15(8):472. PubMed ID: 29925981
    [No Abstract]   [Full Text] [Related]  

  • 19. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
    Upadhyay VA; Brunner AM; Fathi AT
    Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of mutant IDH1 in acute myeloid leukaemia.
    Yaqub F
    Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638561
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.